Rayca Precision

Rayca Precision is a London-based biotechnology company specializing in AI-driven precision oncology. The company leverages its proprietary multi-omics platform, Rayca-X, to analyze complex biological data and predict patient responses to specific therapies with high accuracy. By integrating genomics, transcriptomics, and clinical data, Rayca Precision helps pharmaceutical partners optimize clinical trial design and identify novel biomarkers for patient stratification. Their technology is designed to address the high failure rates in oncology drug development by matching the right treatments to the most responsive patient populations. The company focuses on a variety of solid tumors, including breast and lung cancers, where personalized medicine is most critical.